CL2018001951A1 - Moléculas que activan de manera selectiva las células t reguladoras para tratar enfermedades autoinmunes - Google Patents
Moléculas que activan de manera selectiva las células t reguladoras para tratar enfermedades autoinmunesInfo
- Publication number
- CL2018001951A1 CL2018001951A1 CL2018001951A CL2018001951A CL2018001951A1 CL 2018001951 A1 CL2018001951 A1 CL 2018001951A1 CL 2018001951 A CL2018001951 A CL 2018001951A CL 2018001951 A CL2018001951 A CL 2018001951A CL 2018001951 A1 CL2018001951 A1 CL 2018001951A1
- Authority
- CL
- Chile
- Prior art keywords
- cells
- molecules
- autoimmune diseases
- protein
- selectively activate
- Prior art date
Links
- 210000003289 regulatory T cell Anatomy 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000002699 waste material Substances 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/002,144 US20170204154A1 (en) | 2016-01-20 | 2016-01-20 | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018001951A1 true CL2018001951A1 (es) | 2018-12-28 |
Family
ID=59314394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018001951A CL2018001951A1 (es) | 2016-01-20 | 2018-07-19 | Moléculas que activan de manera selectiva las células t reguladoras para tratar enfermedades autoinmunes |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US20170204154A1 (enExample) |
| EP (1) | EP3405482A4 (enExample) |
| JP (2) | JP6983787B2 (enExample) |
| KR (1) | KR20180100237A (enExample) |
| CN (1) | CN108602871A (enExample) |
| AU (2) | AU2017210187B2 (enExample) |
| BR (1) | BR112018014671A2 (enExample) |
| CA (1) | CA3010621A1 (enExample) |
| CL (1) | CL2018001951A1 (enExample) |
| CO (1) | CO2018008558A2 (enExample) |
| EA (1) | EA201891656A1 (enExample) |
| EC (1) | ECSP18062614A (enExample) |
| MX (1) | MX2018008840A (enExample) |
| SG (1) | SG11201805784PA (enExample) |
| WO (1) | WO2017127514A1 (enExample) |
| ZA (1) | ZA201804458B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3172227T3 (da) * | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN110167957A (zh) * | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| CA3115461A1 (en) * | 2018-03-09 | 2019-09-12 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
| AU2019233581B2 (en) | 2018-03-13 | 2025-08-28 | Cancer Research Technology Limited | Anti-CD25 for tumour specific cell depletion |
| US11359000B2 (en) | 2018-03-28 | 2022-06-14 | Bristol-Myers Squibb Company | Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use |
| US12459980B2 (en) | 2018-07-25 | 2025-11-04 | AskGene Pharma, Inc. | IL-21 prodrugs and methods of use thereof |
| CA3108865A1 (en) | 2018-08-06 | 2020-02-13 | Medikine, Inc. | Il-2 receptor binding compounds |
| KR20250154552A (ko) * | 2018-09-27 | 2025-10-28 | 실리오 디벨럽먼트, 인크. | 마스킹된 사이토카인 폴리펩타이드 |
| CN113286814A (zh) * | 2018-10-31 | 2021-08-20 | 德里尼亚公司 | 多价调节性t细胞调节子 |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| WO2020252264A1 (en) | 2019-06-12 | 2020-12-17 | AskGene Pharma, Inc. | Novel il-15 prodrugs and methods of use thereof |
| PH12022550165A1 (en) | 2019-07-26 | 2023-05-08 | Visterra Inc | Interleukin-2 agents and uses thereof |
| AU2020329933A1 (en) * | 2019-08-15 | 2022-03-24 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof |
| KR20220066116A (ko) * | 2019-09-16 | 2022-05-23 | 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 | 재조합 인간 뉴레귤린 유도체 및 그의 용도 |
| AU2020378282B2 (en) | 2019-11-05 | 2023-05-18 | Medikine, Inc. | Dual IL-2R and IL-7R binding compounds |
| JP7427286B2 (ja) | 2019-11-05 | 2024-02-05 | メディカイン、インコーポレイテッド | ＩＬ－２ＲβγＣ結合化合物 |
| US20210188934A1 (en) * | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
| WO2021140416A2 (en) | 2020-01-10 | 2021-07-15 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides and uses thereof |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | ＩＬ－７Ｒα結合化合物 |
| KR20220139918A (ko) | 2020-02-03 | 2022-10-17 | 메디카인 인코포레이티드 | IL-7Rαγc 결합 화합물 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| TWI815194B (zh) * | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| WO2022094275A1 (en) | 2020-10-29 | 2022-05-05 | Bristol-Myers Squibb Company | Fusion proteins for the treatment of disease |
| EP4251187A4 (en) | 2020-11-25 | 2025-09-10 | Xilio Dev Inc | TUMOR-SPECIFIC CLASSIBLE LINKERS |
| EP4255466A1 (en) | 2020-12-04 | 2023-10-11 | Visterra, Inc. | Methods of using interleukin-2 agents |
| CN113789346A (zh) * | 2021-08-25 | 2021-12-14 | 北京伟德杰生物科技有限公司 | 长效化重组人白细胞介素2融合蛋白及其制备方法和应用 |
| MX2024009868A (es) * | 2022-02-11 | 2024-08-20 | Visterra Inc | Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias. |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| CN115322260A (zh) * | 2022-06-13 | 2022-11-11 | 杭州高田生物医药有限公司 | 能够在肠道内富集且增殖调节性t细胞的融合蛋白及应用 |
| WO2024054868A1 (en) * | 2022-09-07 | 2024-03-14 | Xencor, Inc. | An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis |
| CN121002050A (zh) * | 2023-02-21 | 2025-11-21 | 艾诺康医药公司 | 编码经修饰的白细胞介素2（il2）多肽的多核苷酸以及其制备和使用方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US5466447A (en) | 1988-06-29 | 1995-11-14 | Amgen Inc. | Method for treating psoriasis |
| JPH03500415A (ja) | 1988-07-05 | 1991-01-31 | アムジエン・インコーポレーテツド | インターロイキン２類似体 |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US6541610B1 (en) | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| AU5134693A (en) | 1993-09-21 | 1995-04-10 | Amgen, Inc. | Method for treating psoriasis |
| CA2320403A1 (en) | 1998-02-25 | 1999-09-02 | Lexigen Pharmaceuticals Corporation | Enhancing the circulating half-life of antibody-based fusion proteins |
| FI104522B (fi) | 1998-04-28 | 2000-02-15 | Abb Control Oy | Kytkinvarokerunko |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6348192B1 (en) | 1999-05-11 | 2002-02-19 | Bayer Corporation | Interleukin-2 mutein expressed from mammalian cells |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001062827A2 (en) | 2000-02-22 | 2001-08-30 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| CN1317301C (zh) | 2000-09-14 | 2007-05-23 | 贝斯以色列护理医疗中心有限公司 | Il－2－和il－15－介导的t细胞应答的调节 |
| BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| IL159524A0 (en) | 2001-07-11 | 2004-06-01 | Maxygen Holdings Ltd | G-csf conjugates |
| DE60222914T2 (de) | 2001-07-27 | 2008-07-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Systeme zur stellengerichteten in-vivo-mutagenese mit oligonukleotiden |
| WO2003015697A2 (en) | 2001-08-13 | 2003-02-27 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| PT1454138E (pt) | 2001-12-04 | 2012-03-28 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| WO2004060867A2 (en) | 2003-01-02 | 2004-07-22 | Timothy Kirk Gallaher | Secreted protein factor and cell membrane-bound splice variant |
| CA2528591C (en) | 2003-06-12 | 2013-01-08 | Eli Lilly And Company | Glp-1 analog fusion proteins |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
| JP2007500132A (ja) * | 2003-07-25 | 2007-01-11 | アムジェン インコーポレイテッド | Ｌｄｃａｍのアンタゴニストおよびアゴニスト、並びにその使用法 |
| AU2005227263A1 (en) | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
| WO2006081510A2 (en) | 2005-01-27 | 2006-08-03 | Novartis Vaccines And Diagnostics Inc. | Methods for treating renal cell carcinoma |
| ES2289663T3 (es) | 2005-02-07 | 2008-02-01 | Novartis Vaccines And Diagnostics, Inc. | Preparacion de aldesleucina para uso farmaceutico. |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| FR2918770B1 (fr) | 2007-07-10 | 2009-09-11 | Essilor Int | Afficheur destine a etre integre a une paire de lunettes. |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| MX2011007647A (es) | 2009-01-21 | 2011-09-01 | Amgen Inc | Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes. |
| CN102356092B (zh) | 2009-03-20 | 2014-11-05 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| BRPI1009716A2 (pt) | 2009-06-15 | 2016-10-11 | Biokine Therapeutics Ltd | ligações péptidicas de quemoquina, capazes de inibir o curso da autoimunidade, inflamação e câncer |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| KR20200070407A (ko) | 2010-11-12 | 2020-06-17 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
| CN102462837B (zh) | 2010-11-19 | 2016-08-03 | 生物林格斯Ip有限公司 | 抗炎组合物 |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| CN102174111B (zh) | 2011-01-25 | 2013-01-09 | 江苏省弗泰生物科技有限公司 | 人白介素2-Fc融合蛋白及其用途 |
| LT3075745T (lt) | 2011-02-10 | 2018-11-26 | Roche Glycart Ag | Mutavę interleukino-2 polipeptidai |
| BR112013023151A2 (pt) | 2011-03-11 | 2020-09-15 | Assistance Publique - Hôpitaux De Paris | interleucina-2 para uso no tratamento de desordem auto-imune, !muno-relacionada ou inflamatória e método para determinar se um regime ou dose de il-2 tem de ser modificado |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| JP2014094898A (ja) * | 2012-11-07 | 2014-05-22 | Univ Of Tsukuba | 炎症性腸疾患に関連する、ＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品、ならびにＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用 |
| US9546203B2 (en) | 2013-03-14 | 2017-01-17 | Amgen Inc. | Aglycosylated Fc-containing polypeptides with cysteine substitutions |
| CA3093606A1 (en) * | 2013-03-15 | 2014-09-18 | Xencor, Inc. | Heterodimeric proteins for induction of t cells |
| CN103193887B (zh) | 2013-04-03 | 2015-02-04 | 江苏众红生物工程创药研究院有限公司 | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 |
| US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| PE20161324A1 (es) | 2014-02-06 | 2016-11-25 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas |
| JP6592505B2 (ja) | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| KR20150133576A (ko) | 2014-05-20 | 2015-11-30 | 삼성전자주식회사 | 화학적 개질된 표적화 단백질 및 그의 이용 |
| DK3172227T3 (da) | 2014-07-21 | 2019-12-02 | Delinia Inc | Molekyler der selektivt aktiverer regulatoriske t-celler til behandlingen af autoimmune sygdomme |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| WO2016057651A1 (en) | 2014-10-09 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Multiple-variable il-2 dose regimen for treating immune disorders |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| KR20240115933A (ko) | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CN110167957A (zh) | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
-
2016
- 2016-01-20 US US15/002,144 patent/US20170204154A1/en not_active Abandoned
-
2017
- 2017-01-19 CA CA3010621A patent/CA3010621A1/en active Pending
- 2017-01-19 SG SG11201805784PA patent/SG11201805784PA/en unknown
- 2017-01-19 EP EP17741904.1A patent/EP3405482A4/en not_active Withdrawn
- 2017-01-19 CN CN201780007419.1A patent/CN108602871A/zh active Pending
- 2017-01-19 MX MX2018008840A patent/MX2018008840A/es unknown
- 2017-01-19 WO PCT/US2017/014090 patent/WO2017127514A1/en not_active Ceased
- 2017-01-19 EA EA201891656A patent/EA201891656A1/ru unknown
- 2017-01-19 AU AU2017210187A patent/AU2017210187B2/en not_active Ceased
- 2017-01-19 BR BR112018014671A patent/BR112018014671A2/pt not_active Application Discontinuation
- 2017-01-19 KR KR1020187023925A patent/KR20180100237A/ko not_active Ceased
- 2017-01-19 JP JP2018538769A patent/JP6983787B2/ja not_active Expired - Fee Related
- 2017-09-06 US US15/696,811 patent/US10294287B2/en active Active
-
2018
- 2018-07-03 ZA ZA2018/04458A patent/ZA201804458B/en unknown
- 2018-07-19 CL CL2018001951A patent/CL2018001951A1/es unknown
- 2018-08-15 CO CONC2018/0008558A patent/CO2018008558A2/es unknown
- 2018-08-20 EC ECSENADI201862614A patent/ECSP18062614A/es unknown
-
2019
- 2019-02-05 US US16/267,583 patent/US10875901B2/en not_active Expired - Fee Related
- 2019-03-13 US US16/352,249 patent/US10766938B2/en not_active Expired - Fee Related
- 2019-03-13 US US16/352,003 patent/US10774126B2/en not_active Expired - Fee Related
- 2019-12-30 US US16/729,698 patent/US11535657B2/en active Active
-
2020
- 2020-11-06 US US17/091,190 patent/US20210070828A1/en not_active Abandoned
-
2021
- 2021-10-26 AU AU2021257949A patent/AU2021257949A1/en not_active Abandoned
- 2021-11-24 JP JP2021189835A patent/JP2022058337A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112018014671A2 (pt) | 2018-12-11 |
| US20190153058A1 (en) | 2019-05-23 |
| US20190202881A1 (en) | 2019-07-04 |
| US20200115429A1 (en) | 2020-04-16 |
| WO2017127514A1 (en) | 2017-07-27 |
| EA201891656A1 (ru) | 2018-12-28 |
| AU2021257949A1 (en) | 2021-11-25 |
| EP3405482A1 (en) | 2018-11-28 |
| JP6983787B2 (ja) | 2021-12-17 |
| JP2019507589A (ja) | 2019-03-22 |
| CO2018008558A2 (es) | 2018-08-21 |
| AU2017210187A1 (en) | 2018-07-19 |
| JP2022058337A (ja) | 2022-04-12 |
| ECSP18062614A (es) | 2018-10-31 |
| SG11201805784PA (en) | 2018-08-30 |
| US10774126B2 (en) | 2020-09-15 |
| US20170204154A1 (en) | 2017-07-20 |
| ZA201804458B (en) | 2019-09-25 |
| KR20180100237A (ko) | 2018-09-07 |
| MX2018008840A (es) | 2018-11-09 |
| CN108602871A (zh) | 2018-09-28 |
| US10294287B2 (en) | 2019-05-21 |
| US11535657B2 (en) | 2022-12-27 |
| US20210070828A1 (en) | 2021-03-11 |
| EP3405482A4 (en) | 2019-06-26 |
| CA3010621A1 (en) | 2017-07-27 |
| US20190202882A1 (en) | 2019-07-04 |
| US20180037624A1 (en) | 2018-02-08 |
| US10766938B2 (en) | 2020-09-08 |
| US10875901B2 (en) | 2020-12-29 |
| AU2017210187B2 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001951A1 (es) | Moléculas que activan de manera selectiva las células t reguladoras para tratar enfermedades autoinmunes | |
| MX2017000821A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes. | |
| CY1124293T1 (el) | Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου | |
| ECSP20081591A (es) | Proteínas de fusión que comprenden progranulina | |
| CL2018003563A1 (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| MX2017000833A (es) | Variantes il-2 modificadas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunitarias. | |
| GEP20237528B (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
| SV2018005781A (es) | Proteinas de fusión gdf15 y usos de éstas | |
| MX2022007894A (es) | Receptores de antigeno quimerico condicionalmente activos para celulas t modificadas. | |
| MX2019001223A (es) | Moduladores de receptores de quimioquina y usos de los mismos. | |
| CL2018000358A1 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| CL2017000603A1 (es) | Tratamiento de la fibrodisplasia osificante progresiva | |
| MX384205B (es) | Metodos para usar agonistas de fxr. | |
| CL2015002686A1 (es) | Muteínas de interleucina-2 para la expansion de células t reguladoras | |
| CO2017001573A2 (es) | Receptor quimérico de antígeno anti-cd123 | |
| PH12018501955B1 (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| EA202091342A2 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| BR112016024515A2 (pt) | proteínas do agonista do receptor trail de cadeia única | |
| CY1122644T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| EA201791508A1 (ru) | Способы трансдифференцировки и способы их использования | |
| CR20200404A (es) | Anticuerpos anti-klk5 y métodos de uso | |
| EP4570317A3 (en) | Compounds for the treatment of bovine or swine respiratory disease | |
| CY1122784T1 (el) | Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1 | |
| EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
| ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos |